Differentiated approach to the treatment of chronic conjunctivitis in post-COVID syndrome based on data laser doppler flowmetry

Purpose: to develop a differentiated approach to the treatment of chronic conjunctivitis in post-Covid syndrome based on laser Doppler flowmetry (LDF) data.

Material and methods. The study included 66 patients (132 eyes) with chronic non-infectious conjunctivitis in the post-Covid period. All patients underwent LGF of the bulbar conjunctiva 3 months after SARS-CoV-2 infection. According to the results of LDF, patients were divided into 2 groups: 1-st with hyperemic and 2-nd with stagnant hemodynamic type of microcirculation. In each group, two subgroups were identified. Patients of subgroup 1-a (18 patients, 36 eyes) were prescribed topical antioxidant agent 3 times a day for 2 months, moisturizing preparations containing sodium hyaluronate 3 times a day, preparation containing heparin during the whole period of observation, systemically a preparation from the group of metabolic agents for 3 months. Patients of subgroup 2-a (15 patients, 30 eyes) were recommended instillations of preparations containing sodium hyaluronate 3 times a day, a preparation containing heparin during the whole period of observation and systemic administration of a preparation from the group of venotonics 3 months. Patients of subgroups 1-b and 2-b were treated with a preparation containing sodium hyaluronate 3 times a day. The effectiveness of therapy was monitored after 1, 3, 6 months.

Results. After therapy hemodynamic parameters of microcirculation significantly improved. Correction of microcirculatory disorders contributed to normalization of perfusion in 3 months in patients of subgroup 1-a (M = 24.8 ± 5.5 p. u.), in 6 months in patients of subgroup 2-a (M = 26.3 ± 6.1 p. u.) and mechanisms of its regulation in 6 months in patients of subgroup 2-a (Kv = 15.2 ± 7.4 %). No statistically significant changes in microcirculatory parameters were registered in patients of subgroups 1-b and 2-b.

Conclusion. Hyperemic or stagnant type of hemodynamic microcirculatory disorders, established by the evaluation of baseline indices (M, σ, Kv), serves as a basis for the choice of treatment tactics for chronic conjunctivitis in postconcussive syndrome.

1. Zayet S, Zahra H, Royer PY, et al. Post-COVID-19 syndrome: Nine months after SARS-CoV-2 infection in a cohort of 354 patients: Data from the first wave of COVID-19 in Nord Franche-Comté Hospital, France. Microorganisms. 2021; 9 (8): 1719. doi: 10.3390/microorganisms9081719

2. Puntmann VO, Martin S, Shchendrygina A, et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med. 2022; 28 (10): 2117–23. doi: 10.1038/s41591-022-02000-0

3. Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM; Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022; 400 (10350): 452–61. doi: 10.1016/S0140-6736(22)01214-4

4. Isaeva A.V., Vetluzhskaya M.V., Korobeynikova A.N., Vlasova A.V. Clinical phenotypes and features of the post-COVID syndrome course. Russian journal of preventive medicine. 2023; 26 (9): 66–73 (In Russ.). doi: 10.17116/profmed20232609166

5. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022; 22 (4): e102-e107. doi: 10.1016/S1473-3099(21)00703-9

6. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021; 53 (10): 737–54. doi: 10.1080/23744235.2021.1924397

7. Chen C, Haupert SR, Zimmermann L, et al. Global prevalence of postCoronavirus disease 2019 (COVID-19) condition or long COVID: a metaanalysis and systematic review. J Infect Dis. 2022; 226 (9): 1593–607. doi: 10.1093/infdis/jiac136

8. Líška D, Liptaková E, Babičová A, et al. What is the quality of life in patients with long COVID compared to a healthy control group? Front Public Health. 2022; 10: 975992. doi: 10.3389/fpubh.2022.975992

9. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38: 101019. doi: 10.1016/j.eclinm.2021.101019

10. Perlis RH, Lunz Trujillo K, Safarpour A, et al. Association of Post-COVID-19 condition symptoms and employment status. JAMA Netw Open. 2023; 6 (2): e2256152. doi: 10.1001/jamanetworkopen.2022.56152

11. Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs. 2022; 36 (7): 681–702. doi: 10.1007/s40263-022-00931-3

12. Mantovani A, Morrone MC, Patrono C, et al. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022; 29 (10): 1891–900. doi: 10.1038/s41418-022-01052-6

13. Bahmer T, Borzikowsky C, Lieb W, et al. Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: A prospective, multicentre, population-based cohort study. EClinicalMedicine. 2022; 51: 101549. doi: 10.1016/j.eclinm.2022.101549

14. Asfandiyarova N.S. Post-COVID syndrome. Klinicheskaya meditsina. 2021; 99 (7–8): 429–35 (In Russ.).

15. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022; 23 (2): 210–6. doi: 10.1038/s41590-021-01113-x

16. Kalyuzhnaya E.N., Ponomareva M.N., Petrov I.M., et al. Etiopathogenetic therapy effect on the microcirculation of the bulbar conjunctiva in patients with dyslipidemia after COVID-19 associated pneumonia. Russian ophthalmological journal. 2021; 14 (2): 7–13 (In Russ.). https://doi.org/10.21516/2072-0076-2021-14-2-7-13

17. Chandra A, Seidelmann SB, Claggett BL, et al. The association of retinal vessel calibres with heart failure and long-term alterations in cardiac structure and function: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2019; 21 (10): 1207–15. doi: 10.1002/ejhf.1564

18. Gnthner R, Streese L, Angermann S, et al. Mortality prediction of retinal vessel diameters and function in a long-term follow-up of haemodialysis patients. Cardiovasc Res. 2022; 118 (16): 3239–49. doi: 10.1093/cvr/cvac073

19. Safonova T.N., Lutsevich E.Е., Kintukhina N.P. Microcirculatory changes in bulbar conjunctiva in various diseases. Vestnik oftal’mologii. 2016; 132 (2): 90–5 (In Russ.). https://doi.org/10.17116/oftalma2016132290-95

20. Safonova T.N., Kintyukhina N.P., Yartsev V.D. Morphofunctional substantiation of repeated invasive treatment of chronic blepharitis. Vestnik oftal’mologii. 2021; 137 (1): 21–7 (In Russ.). https://doi.org/10.17116/oftalma202113701121

21. Safonova T.N., Zaitseva G.V., Kintyukhina N.P. The effect of a new coronavirus infection caused by the SARS-CoV-2 virus on microcirculation in the conjunctiva. Meditsinskiy Sovet. 2022; 16 (14): 206–11 (In Russ.). https://doi.org/10.21518/2079-701X-2022-16-14-206-211

22. Safonova T.N., Zajceva G.V., Kintyuhina N.P., Medvedeva E.S. A method for correcting microcirculatory disorders in post-COVID syndrome. Patent RF № 2791660, 13.03.2023 (In Russ.).

23. Safonova TN, Zaitseva GV. Pathogenetic mechanisms of dry eye syndrome in a novel coronavirus infection caused by SARS-CoV-2. Russian Open Medical Journal. 2022; 11: e0306. doi: 10.15275/rusomj.2022.0306

24. Litvitskiy P.F. Regional blood flow and microcirculation disorders. Regional hemodynamics and microcirculation. 2020; 19 (1): 82–92 (In Russ.). https://doi.org/10.24884/1682-6655-2020-19-1-82-92

25. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020; 2 (7): e437-e445. doi: 10.1016/S2665-9913(20)30121-1

26. Putilina M.V. Algorithm of diagnostics and therapy of chronic forms of venous circulation disorders. Lechashchii vrach. 2015 (6): 66–72 (In Russ.).

27. Bogachev V.Yu., Mansilla A., Boldin B.V., Rodionov S.V., Dzhenina O.V. Pathogenetic substantiation of phlebotropic therapy for chronic venous diseases. Нospitalreplacing technologies: Ambulatory surgery. 2019; (3–4): 19–33 (In Russ.). https://doi.org/10.21518/1995-1477-2019-3-4-19-33

28. Hanssen H, Streese L, Vilser W. Retinal vessel diameters and function in cardiovascular risk and disease. Prog Retin Eye Res. 2022; 91: 101095. doi: 10.1016/j.preteyeres.2022.101095

29. Aydemir E, Aydemir GA, Atesoglu HI, et al. The impact of coronavirus disease 2019 (COVID-19) on retinal microcirculation in human subjects. Klin Monbl Augenheilkd. 2021; 238 (12): 1305–11. doi:10.1055/a-1579-0805